Randomized Controlled Trial
Copyright ©The Author(s) 2025.
World J Gastrointest Surg. Jun 27, 2025; 17(6): 103635
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.103635
Table 1 Patient characteristics in the study, n (%)
Characteristics
Total (n = 260)
CEMR (n = 130)
UEMR (n = 130)
P value
Age, median (minimum-maximum)58 (27-85)60 (27-83)59 (32-85)0.9152
Sex0.699
Male165 (63.5)84 (64.6)81 (62.3)
Female95 (36.5)46 (35.4)49 (37.7)
Indication for colonoscopy
Abdominal pain73 (28.1)42 (32.3)31 (23.8)0.129
Screening60 (23.1)24 (18.5)36 (27.7)0.077
Blood in stool34 (13.1)15 (11.5)19 (14.6)0.462
Diarrhea33 (12.7)17 (13.1)16 (12.3)0.852
Constipation33 (12.7)17 (13.1)16 (12.3)0.852
Post-operative CRC23 (8.8)14 (10.8)9 (6.9)0.275
Stool change2 (0.8)0 (0)2 (1.5)0.4981
Weight loss2 (0.8)1 (0.8)1 (0.8)11
Clinical symptoms
No symptom85 (32.7)38 (29.3)47 (36.1)0.234
Abdominal pain74 (28.5)40 (30.8)34 (26.2)0.410
Diarrhea35 (13.5)19 (14.6)16 (12.3)0.586
Blood in stool33 (12.7)17 (13.1)16 (12.3)0.852
Constipation31 (11.9)15 (11.5)16 (12.3)0.848
Weight loss2 (0.8)1 (0.8)1 (0.8)11
Hypertension127 (48.8)62 (47.7)65 (50)0.710
Diabetes20 (7.7)8 (6.2)12 (9.2)0.352
Kidney failure3 (1.2)0 (0)3 (2.3)0.2471
Personal history of CRC11 (4.2)5 (3.8)6 (4.6)0.758
Family history of CRC4 (1.5)2 (1.5)2 (1.5)11
Table 2 Endoscopic and pathological characteristics of the colorectal lesions, n (%)
Characteristics
Total (n = 260)
CEMR (n = 130)
UEMR (n = 130)
P value
Location of lesion
Rectum67 (25.8)28 (21.5)39 (30.0)0.119
Sigmoid colon98 (37.7)52 (40.0)46 (35.4)0.443
Descending colon16 (6.2)10 (7.7)6 (4.6)0.302
Transverse colon34 (12.3)17 (13.1)17 (13.1)1
Ascending colon36 (13.8)18 (13.8)18 (13.8)1
Cecum9 (3.5)5 (3.8)4 (3.1)11
Size, median (minimum-maximum) (mm)20 (10-30)12 (10-30)12 (10-25)0.7582
10-19233 (89.6)117 (90.0)116 (89.2)0.839
20-3027 (10.4)13 (10.0)14 (10.8)
Paris classification0.600
0-Is172 (66.1)88 (67.7)84 (64.6)
0-IIa/0-IIb88 (33.9)42 (32.3)46 (35.4)
NICE classification0.656
Type 122 (8.5)10 (7.7)12 (9.2)
Type 2238 (91.5)120 (92.3)118 (90.8)
WHO classification
Nonneoplastic polyp14 (5.4)6 (4.6)8 (6.2)0.583
Tubular adenoma161 (61.9)76 (58.5)85 (65.4)0.250
Tubulo-villous adenoma36 (13.8)21 (16.2)15 (11.5)0.281
Serrated lesion49 (18.8)27 (20.8)22 (16.9)0.428
Vienna classification
No dysplasia21 (8.1)9 (6.9)12 (9.2)0.495
Low-grade dysplasia209 (80.4)108 (83.1)101 (77.7)0.274
High-grade dysplasia26 (10.0)10 (7.7)16 (12.3)0.215
Superficial cancer4 (1.5)3 (2.3)1 (0.8)0.6221
Table 3 Study outcomes (intention-to-treat analysis), n (%)
Outcomes
CEMR (n = 130)
UEMR (n = 130)
P value
En bloc resection0.0141
Yes123 (94.6)130 (100)
No7 (5.4)0 (0)
R00.007
Yes112 (90.3)120 (98.4)
No12 (9.7)2 (1.6)
Procedure time (IQR), second185 (35-900)65 (15-610)< 0.0012
Bleeding0.003
Yes13 (10.0)2 (1.5)
No117 (90.0)128 (98.5)
Hemoclip (IQR)3 (1-9)2 (1-9)< 0.0012
Table 4 Study outcomes (per-protocol analysis), n (%)
Outcomes
CEMR (n = 124)
UEMR (n = 122)
P value
En bloc resection0.0141
Yes117 (94.4)122 (100)
No7 (5.6)0 (0)
R00.007
Yes112 (90.3)120 (98.4)
No12 (9.7)2 (1.6)
Procedure time (IQR), second185 (35-900)65 (15-610)< 0.0012
Bleeding0.004
Yes13 (10.5)2 (1.6)
No111 (89.5)120 (98.4)
Hemoclip (IQR)3 (1-9)2 (1-9)< 0.0012